Biogen (BIIB) PT Lowered to $301 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $219.88 -1.32%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Biogen (NASDAQ: BIIB) to $301.00 (from $302.00) while maintaining a Underweight rating.
You May Also Be Interested In
- Biogen reports 52-week phase 2 data for lupus skin drug litifilimab
- JPMorgan Upgrades Arafura Rare Earths (ARU:AU) to Neutral
- JPMorgan Upgrades Sandfire Resources NL (SFR:AU) (SNDFY) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
